Finding the Role of Anifrolumab in the New Paradigm of Systemic Lupus Erythematosus Treatment.
J Rheumatol
; 2024 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-39353646
ABSTRACT
The article by Tani et al, "Anifrolumab in Refractory Systemic Lupus Erythematosus A Real-World, Multicenter Study,"1 evaluates the efficacy of anifrolumab (ANI) in patients with systemic lupus erythematosus (SLE) who failed to respond to other treatments, including biologics.There are many unmet needs in the treatment of SLE. Despite recent advances, remission and low disease activity (LDA) rates remain suboptimal; therefore, some patients with SLE are at high risk of developing endstage renal disease, organ damage, drug-related toxicities-particularly related to the prolonged use of glucocorticoids (GCs)-and premature mortality.2-4.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Rheumatol
Year:
2024
Document type:
Article
Affiliation country:
Argentina
Country of publication:
Canada